Omecamtiv mecarbil, a cardiac myosin activator being manufactured by Amgen and Cytokinetics to treat heart failure with reduced ejection fraction, has been granted a Fast Track designation by the FDA.

The study's authors emphasized the importance of interventions such as patient communication and education. 

The algorithm, developed as part of a collaboration with Mayo Clinic, received Breakthrough Device designation back in December 2019.

With the disease becoming more and more common in the United States, researchers have been hard at work determining the best possible treatment options.

Rheumatoid arthritis is associated with a greater risk of heart failure, according to new findings published in the Journal of the American Heart Association. The risk increases even more when patients have higher levels of C-reactive protein, a telltale sign of severe inflammation.  

Mavacamten has demonstrated value as a treatment option for patients with obstructive hypertrophic cardiomyopathy (HCM), according to results from the EXPLORER-HCM phase III clinical trial.

The FDA has approved a new treatment option, Farxiga oral tablets, for adult heart failure patients with reduced ejection fraction.